Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TTR | P02766 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14144881 | 0.85 | MAPT (0.51) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL3657921 | 0.84 | TTR (0.53) | MAPTTTRSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4255534 | 0.82 | TTR (0.41) | MAPTTTRSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL333582 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL29463290 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL580639 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL2500053 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL185845 | 0.81 | CA2 (0.68) | MAPTTTRALDH1A1KDM4ECA2 | |
| SCHEMBL30074670 | 0.81 | CA2 (0.68) | MAPTTTRALDH1A1KDM4ECA2 | |
| SCHEMBL16658437 | 0.81 | MAPT (0.47) | MAPTTTRSMN1; SMN2L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2024102245-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3390370-B1 | BIS-TRIAZOLE COMPOUNDS WITH ANTI-BIOFILM AND ANTI-CORROSION PROPERTIES | UNIV DE TOULON (FR) | 2021-02-03 | — | — | EP | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20180370953-A1 | Bis-Triazole Compounds with Anti-Biofilm and Anti-Corrosion Properties | UNIVERSITÉ DE TOULON (FR) | 2018-12-27 | — | — | US | disclosed |
| EP-3390370-A1 | BIS-TRIAZOLE COMPOUNDS WITH ANTI-BIOFILM AND ANTI-CORROSION PROPERTIES | Université de Toulon (FR) | 2018-10-24 | — | — | EP | disclosed |
| CN-108430979-A | Double triazole compounds with antibiont film and anti-corrosion performance | 土伦·瓦尔大学 | 2018-08-21 | — | — | CN | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017102883-A1 | BIS-TRIAZOLE COMPOUNDS WITH ANTI-BIOFILM AND ANTI-CORROSION PROPERTIES | UNIVERSITÉ DE TOULON (FR) | 2017-06-22 | — | — | WO | disclosed |
| US-6221871-B1 | TREATING SCHIZOPHRENIA, DEPRESSION OR PARKINSON'S DISEASE | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-5912350-A | Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands | NEUROGEN CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| US-5677454-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSONISM | NEUROGEN CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| EP-0793662-A1 | AMINOMETHYL ARYL COMPOUNDS; DOPAMINE RECEPTOR SUBTYPE SELECTIVE LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-10 | — | — | EP | disclosed |
| US-5594141-A | ANTIPSYCHOTIC AND ANTIDEPRESSANT AGENTS; PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996016058-A1 | AMINOMETHYL ARYL COMPOUNDS; DOPAMINE RECEPTOR SUBTYPE SELECTIVE LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370953-A1 | Bis-Triazole Compounds with Anti-Biofilm and Anti-Corrosion Properties | FHIT, FOS, BSG | MAPT 3579/4885TTR 4264/4885SMN1; SMN2 4885/4885 |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | CHRM5, CHRM3, CHRNA3 | MAPT 621/4885TTR 1315/4885SMN1; SMN2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.